Date: Tuesday 14th January 2020
Time: 14:00 - 15:00 GMT
Speaker: Richard Pugh (Mango Solutions)
Registration: To register for this free event, please click here.
Richard Pugh is Mango’s Chief Data Scientist, and has over 20 years’ experience of helping organisations add value with data and advanced analytics. As co-founder of Mango, Richard has led a wide range of ground-breaking data science projects for some of the most forward thinking companies in the world.
During his two decades in the industry, Richard has become a leader in the Data Science field. He started out with a BSc in Mathematics and Statistics from Bath University, which led to work as a consultant in the pharmaceutical sector. In 2002 he co-founded Mango, which allowed him to make his vision of proactive, data driven business culture a reality. In his day-to-day role, Richard spends much of his time advising clients from a variety of industries on data-driven strategies, while keeping up-to-date with the cutting edge commercial applications of data science.
Richard is incredibly passionate about supporting the R and Data Science communities. He co-authored the book “R in 24 Hours”, was the first president of the R Consortium, sits on the RSS Data Science Section Committee and regularly speaks at events. Richard uses his experience to help companies make better decisions through data, and remove any perceived constraints on the limits of data science, sharing that it can inform and transform all aspects of a business.
The ITIT course will take 25 delegates new to the industry on a complete drug development experience from discovery to marketing. They will visit 6 companies to learn about 6 topics from experts in their field. The ITIT course will have 3 sessions in continental Europe and 3 sessions in the UK. The start of the 2020-2021 course will be delayed until face-to-face meetings with up to 30 people are permitted and companies are allowing travel again.
In this webinar you will hear an introduction to what a patient preference study is as well as an overview of where this type of study can inform regulatory decision making. This will be followed by 2 examples looking at potential approaches to eliciting patient preference.
PSI Vaccine SIG Webinar: Statistical Topics on COVID-19 Therapeutic and Vaccine Clinical Trials
We are delighted to be joined by Frank Harrell who will present 'Sequential Bayesian Designs for Rapid Learning in COVID-19 Therapeutic Trials'; and also by Dean Follmann, who will present on 'Statistical Aspects of COVID-19 Vaccine Trials'. Join us for this insightful and highly topical webinar.
PSI, the European Federation of Statisticians in the Pharmaceutical Industry (EFSPI) and the Biopharmaceutical Section of the American Statistical Association (ASA) are jointly organising a webinar on Estimands in Practice. Speakers from regulatory authorities (FDA and EMA) and industry will present on their experience on this topic to date.
Biometrics at AstraZeneca provides the data that influences decisions on how we roll back the frontiers of science to bring life-changing medicines to the world. We are at the heart of design, analytics and interpretation of AstraZeneca’s portfolio.